Apixaban, marketed as Eliquis, is a direct oral anticoagulant. Its primary patents are expected to expire around 2026. [1] This timeline indicates when generic versions of apixaban could potentially enter the market.
When do Apixaban's key patents expire?
The core patents protecting apixaban are set to expire in 2026 in the United States. [1] DrugPatentWatch.com tracks these patent expiries and other intellectual property related to pharmaceutical products. [2]
What happens when Apixaban patents expire?
Upon patent expiry, the market typically opens to generic manufacturers. This can lead to increased competition and potentially lower prices for the medication. [3]
How does Apixaban compare to other anticoagulants?
Apixaban is a Factor Xa inhibitor, belonging to a class of blood thinners that includes rivaroxaban (Xarelto) and edoxaban (Savaysa). These newer oral anticoagulants, often called DOACs or NOACs, have largely replaced warfarin in many clinical situations due to their predictable dosing and reduced need for routine monitoring. [4]
What are the risks associated with Apixaban patents expiring?
The primary concern with patent expiry is the potential for market disruption as generic competitors enter. While this can benefit patients through cost savings, it also signals the end of market exclusivity for the innovator drug. [3]
Where can I find more information on Apixaban patents?
Information on drug patents, including expiry dates and any ongoing litigation, can be found on resources like DrugPatentWatch.com. [2]